Tasman Therapeutics
PrivateLast Round
Series A
Apr 3, 2025
Total Funding Raised
$175M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Tasman Therapeutics operates in Healthcare & Life Sciences and is based in San Francisco, California. Its latest recorded funding round was a Series A round in April 2025.
Tasman Therapeutics is a clinical-stage pharmaceutical company developing innovative treatments for neuropsychiatric disorders, including its lead product candidate R-107, an extended-release oral ketamine tablet for treatment-resistant depression.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Mental Health
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Tasman Therapeutics Comparables
Compare Tasman Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Neurocentrx Pharma | 91% | |
| HMNC Brain Health | 89% | |
| MIRA Pharmaceuticals, Inc. | 80% |
For institutional investors. Book with your work email.
Tasman Therapeutics Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 169% MoM.
- Apr 3, 2025
$175M round completed.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- partners_withAug 12, 2026
On Aug 12th '26 in California, Tasman Therapeutics, Inc. partners with Osmind in a multi-year collaboration that uses Osmind's real-world evidence platform and clinical network to support the R-107 ROCKET Phase 3 program, launch readiness, and commercialization.
For institutional investors. Book with your work email.
Tasman Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Tasman Therapeutics's valuation, stock price, and market status.
Is Tasman Therapeutics a public or private company?
Tasman Therapeutics is a private company.
What is the current stock price of Tasman Therapeutics?
Tasman Therapeutics is a private company, so its shares have no public market price. Caplight tracks Tasman Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Tasman Therapeutics worth (valuation)?
Valuation information for Tasman Therapeutics is not publicly available.
Can I buy Tasman Therapeutics stock?
Tasman Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Tasman Therapeutics's last funding round?
Tasman Therapeutics's most recent funding round was Series A on April 3, 2025.
Who are the main investors in Tasman Therapeutics?
Investor information for Tasman Therapeutics is not publicly disclosed.
Will Tasman Therapeutics IPO soon?
No public IPO plans have been announced for Tasman Therapeutics.
How can I track Tasman Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Tasman Therapeutics's shares on secondary markets.